TMates Review: Plan Prices, Branded Care and Refund Limits

TMates offers a useful choice between compounded treatment packages and branded prescription-management services. The buying decision is how much to commit before the continuing price, prescription supply and refund boundary are clear. We would start with the shorter purchase comparison and identify the treating practice and dispensing pharmacy before choosing a longer plan.

We have not used TMates' treatment. The product-page information available for this review was five to six days old on October 26, 2026. Confirm current prices and terms before paying. The advertisements do not establish a selected prescription or order.

The one-month price is not the annual allocation

The semaglutide page displays a one-month plan at $249 and a twelve-month card totaling $1,900, with a rounded $158 monthly display. The tirzepatide page displays $297 for one month and $1,999 for twelve months, alongside a rounded $167 monthly display. Those lower monthly figures describe the longer plans; they are not the displayed price of buying one month.

The pages advertise medication, ongoing support and shipping, with the same medication price across their listed doses. That does not establish what a clinician would prescribe or how much usable medicine arrives with each shipment.

Before comparing a longer commitment, obtain the actual initial debit, any financing obligation, renewal amount and treatment period. A card total does not settle whether payment is collected upfront or how shipments are divided. Our six-month cost guide helps distinguish a payment schedule from a monthly allocation. We would not turn these displays into a confirmed annual invoice.

The branded $99 buys care, not Wegovy or Zepbound

The Wegovy page advertises $99 per month for clinical evaluation and prescription management. It says an independent provider can send a prescription to the preferred pharmacy and explicitly says TMates does not dispense or ship Wegovy. The Zepbound page makes the same care-only distinction.

The generic FAQ on those pages also describes a program including visits, coaching and medication. That broader description should not erase the specific branded-service limitation. Request separate figures for TMates' service and the pharmacy's medication, along with what happens if a prescription is not issued or cannot be filled.

Do not count on insurance payment merely because a general FAQ mentions major plans. Ask about the exact prescription and pharmacy benefit. The insurance guide explains why coverage assistance and an approval are different things.

An oral button leaves the prescription unfinished

Both compounded product pages have injectable and oral format controls. Semaglutide's explanation mentions injection or an oral option, while tirzepatide's main treatment description remains weekly injection. We did not operate the controls or establish whether selecting oral changes the price.

An oral label alone does not identify a swallowed tablet, dissolving tablet, liquid or another preparation. Obtain the exact ingredient, dosage form, strength, quantity and instructions. Do not assume either oral offer reproduces the exposure, results or approval of a branded medicine. Our oral-versus-injectable guide explains why the formulation matters.

Canceling does not establish a refund

The terms, dated August 12, 2025, allow a full refund before medical-history review and after review if the patient qualifies for none of the medication-assisted weight-loss plans. After qualification, when a prescription has been written and transmitted to a pharmacy, the terms say no refund. An unsuccessful refund request leaves a payment plan in place.

That boundary matters more when considering a longer plan. Ask how it applies to the full commitment, future unfilled supplies and any unused balance. A cancel-anytime banner does not answer those questions. Obtain the renewal date, notice cutoff and confirmation that the intended future charge stops. The cancellation checklist helps organize those records.

The terms permit pricing changes before initial or future billing. Their account-deactivation provision is not a complete recurring-prescription cancellation procedure. We would resolve those details before paying for a longer period.

Identify the platform, practice and pharmacy separately

The terms name TMates Inc. as a technology platform and make independent treating providers responsible for clinical services. The privacy policy separately refers to TMates Medical Group and its notice of privacy practices. That reference does not establish the complete professional-entity name or identify the practice assigned to a patient.

The doctors page makes general board-certification and experience claims without naming an individual in the available text. The About page describes an online pharmacy and manufacturer, while its footer says TMates is not a 503A or 503B compounding facility. The footer also says compounded medicines are not evaluated by the FDA for safety, quality or efficacy. These descriptions do not supply the dispensing branch or establish a manufacturing or pharmacy license.

Ask for the legal treating practice, assigned clinician and actual dispensing pharmacy before relying on general credentials or quality claims. Our pharmacy-verification guide explains the records to check once a facility is identified. We have not independently established a complete clinical and dispensing chain.

Confirm support and state access for the selected treatment

The homepage advertises doctor access across fifty states; the semaglutide FAQ more narrowly says shipping is available to most states and depends on eligibility. Confirm the selected preparation for the patient's location and delivery address. A national network statement is not a product-by-state availability list.

Semaglutide's FAQ says bloodwork may be recommended depending on medical history rather than always required. Ask who orders and reviews any needed tests and what they cost. The contact page advertises weekday support hours and a response within twenty-four hours; that is not a tested clinician-response standard for symptoms.

Our recommendation

TMates is worth comparing when the distinction between a medication bundle and branded care-only service is useful. Its public plan menu helps show the tradeoff between a shorter purchase and a lower allocation over a longer commitment. The unresolved prescription, renewal and refund details limit how confidently those figures can support a purchase.

We would choose a longer plan only after receiving a clear payment schedule, usable supply, care and pharmacy identities, and the treatment of an unused balance. If those answers remain unavailable, compare a service that provides them before payment. A larger initial commitment should buy clarity as well as a lower advertised allocation.